key: cord-1012915-47g343sf
authors: Sereno, María; Gutiérrez-Gutiérrez, Gerardo; Sandoval, Carmen; Falagan, Sandra; Jimenez-Gordo, Ana María; Merino, María; López-Menchaca, Ramiro; Martín, Patricia Martínez; Roa, Silvia; Casado, Enrique
title: A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: is immunosuppression a risk factor for SARS-COV2 infection?
date: 2020-05-04
journal: Lung Cancer
DOI: 10.1016/j.lungcan.2020.04.029
sha: 5d427caefcfb8b4c38cb74fd2534f5d1b478da69
doc_id: 1012915
cord_uid: 47g343sf

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 

Some authors suggest that cancer induces an overexpression of immunosuppressive cytokines, dysfunctional leukocyte population and an abnormal dendritic cell maturation implying a lower risk for hyper inflammatory response (HIR) and SARS [3] . Therefore, all these events, could explain a lower risk for (HIR) associated to SARS-cov-2 infection after the initial virus clearance [4] .

Consequently, in cancer patients could happened two opposite effects in SARS-cov2 infection setting: one effect could be a major vulnerability during the viral phase because of the cellular immunosuppression (IMS) and a second effect related with a certain protection for the HIR because of humoral as well as cellular IMS [5] . Frequent comorbidities in cancer like advanced age, CVD, DM, smoking status, LD may also modulate the risk.

In this patient, the young age with no CVD, and the presence of severe IMS and steroid treatment, could be hypothesized to explain the favorable prognosis. A recent case report published by Bomoni et al, described an advanced lung cancer patient treated with Nivolumab (antiPD-1) who presented a rapidly respiratory deterioration because COVID-19 disease. The lack of steroids administration could have influenced this course [6] .

In our patient, neutropenia could have had a protective role. G-CSF receptor targeting in animal models of influenza pneumonia has been reported to reduce neutrophil trafficking and pulmonary edema without affecting viral clearance [7] . In addition, GM-CSF seems to play an important role in infection control by stimulating granulopoiesis and by improving microbicide functions of monocytes and granulocytes [8] . Also, GM-CSF 

Detection of SARS-CoV-2 in different types of clinical specimens

He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?

Myeloid suppressor cells in cancer and autoimmunity

A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab

G-CSFR antagonism reduces neutrophilic inflammation during pneumococcal and influenza respiratory infections without compromising clearance. Sci Rep

Functions of granulocyte-macrophage colony-stimulating factor

GM-CSF Down-Regulates TLR Expression via the Transcription Factor PU.1 in Human Monocytes

Does recombinant human

To Eduardo Gutiérrez Gutiérrez for his contribution in English review and manuscript redaction